Extracellular-regulated kinase (ERK2) has been regarded as an essential target for various cancers, especially melanoma. Recently, pyrrolidine piperidine derivatives were reported as Type I inhibitors.
Introduction
The Ras/MAPK (RAF/MEK/ERK) signaling transduction is a key pathway of cellular proliferation, differentiation and survival downstream of RAS activation. [1] [2] [3] Not surprisingly, this pathway is frequently deregulated in human cancers, such as melanoma. 4, 5 The extracellular-regulated kinases (ERK1 and ERK2) are central in the pathway downstream of Ras, Raf, and MEK kinases, while ERK1 and ERK2 show 89% sequence identity within the kinase domains. Activation/phosphorylation of ERK promotes tumor growth, cell cycle progression and survival through transcriptional activation, for example, ERK1/2 was found constitutively activated in 60% of melanoma cells. 6 Therefore, the ERK1/2 kinase is the central node of the RAS/ MAPK pathway. The greatest advantage of targeting ERK1/2 is that no mutations have been found in ERK1/2.
7,8
Despite ERK1/2 inhibitors playing an important role in the MAPK pathway, few ERK1/2 inhibitors have been reported in the literature, and no known ERK1/2 inhibitor has entered advanced clinical trials. [9] [10] [11] So, development of potential ERK1/2 inhibitors is extremely urgent. The majority of reported ERK1/2 inhibitors are ATP competitive inhibitors, which belong to Type I kinase inhibitors, such as VTX-11e, 10 FR180204 (ref. 12 ) and GDC-0994. 13 Apirat et al. reported that inhibitor SCH772984 simultaneously binds to the ATP binding pocket and the allosteric pocket. The allosteric pocket is adjacent to the ATP binding pocket, which located between P-loop and aC helix. As a Type I 1/2 kinase inhibitor, SCH772984 is a promising inhibitor targeting ERK1/2 with high bioactivity, and we have previously studied the interaction mechanisms of SCH772984 with ERK2.
14 Aerwards, Deng and coworkers discovered compound 1 as an effective selective ERK2 inhibitor through the automated ligand identication system (ALIS), 15 and meanwhile they obtained the crystal structure of human ERK2 bound compound 1 (PDB ID: 4QYY 16 ). As shown in Fig. 1 , the binding mode of compound 1 to ERK2 is similar with that of SCH772984 to ERK2. In detail, ERK2 adapts a "DFG in" mode, and compound 1 forms hydrogenbonding interaction with the residues Lys52, Gln103, Asp104 and Met106. Chlorophenyl forms hydrophobic interaction with the hinge region and catalytic loop region of ERK2. Besides, the acetyl phenyl interacts "face to face" with the Tyr62 side chain through an aromatic p-p interaction, which may be critical to improve the potencies of ERK2 Type I 1/2 inhibitors.
Based on the structures of the compounds already reported, investigating the interaction mechanisms of these compounds with ERK2 is of great signicance for discovering efficient and potential ERK2 inhibitors. Therefore, in this study, a combined computational modeling strategy, based on molecular docking, molecular dynamics (MD) simulations, free energy calculations and free energy decomposition analysis, was employed to understand the interaction between ERK2 and Type I 1/2 inhibitors and identify several key structures that are important to the efficiency of inhibitors. The use of rigid protein structures may hinder the correct prediction of ligand binding posture and relative binding capacity due to the dynamic behavior of kinase in binding of Type I 1/2 inhibitors. [17] [18] [19] Herein, various molecular modeling techniques were used to handle the exibility of ERK2, including ensemble docking and MD simulations and inducedt docking (IFD), IFD simulates the induced t by rening the side chain conformation of important residues located in active site. Ensemble docking is based on the use of multiple receptor conformation (MRC) in molecular docking to combine protein exibility. 20, 21 In this study, MD simulations and structural generate an ensemble of MRC for ERK2, and then was utilized for ERK2 docking with Type I 
Materials and methods

Preparing systems
The co-crystallized structures of two known inhibitors bound with ERK2 were retrieved from the RCSB Protein Data Bank (PDB ID codes: 4QTA 22 and 4QYY
16
). The missing residues were added using the Prime module in Schrodinger 2009. 23 Aer that the two structures were prepared by the Protein Preparation Wizard in Schrodinger 2009, including adding assigning protonation states, side chains of residues and hydrogen atoms, and relaxing the amino residue side chains of the proteins.
The 3D structures of all the 27 inhibitors 16,24 were sketched by Maestro and preprocessed by LigPrep, which generated the low energy 3D conformers for each compound with the OPLS-2005 force eld. The ionized state was assigned by using Epik at a target pH value of 7.0 AE 2.0. Default settings were used for the other parameters. The 2D structures of all the 27 compounds and their biological activities against ERK2 are summarized in Table 1 .
Generation of multiple representative ERK2 protein conformations
Based on the two resolved crystal structures (PDB codes: 4QTA and 4QYY), the representative ERK2 conformations for ensemble docking were generated by molecular dynamics (MD) simulations. The partial charges of the two inhibitors in 4QTA and 4QYY were tted using the RESP methodology based on the electrostatic potentials computed at the HF/6-31G(d) level of theory. [25] [26] [27] The AMBER99SB 28 and GAFF force elds were used for the proteins and inhibitors, respectively. 29 Then, Na + ions were added to neutralize the net charge of the two complexes, and last the two systems were solvated into a 10Å cubic TIP3P water 30 box.
All of the MD simulations were performed with the NAMD 2.9 simulation package. 31 The specic parameter settings refer to our previous work. 32 Particle Mesh Ewald (PME) algorithm 33 was employed to treat long-range electrostatic interactions, while the cutoff for the short-range nonbonded interactions were set to 10Å. All bonds involving hydrogen atoms were restrained using the SHAKE algorithm, and the time step was set to 2 fs. During the sampling process, the coordinates of each complex were saved every 1 ps.
For each complex structure, 200 conformations were evenly extracted from the nal stable 10 ns MD trajectories, and then clustered into 10 categories using the k-means clustering method based on the RMSDs within 5Å in the ligand binding pocket in the extracted MD conformations. At last, 10 representative structures chosen from 10 clusters were generated.
Docking protocols
According to the two crystal structures 4QTA and 4QYY, the studied 27 inhibitors were docked into the binding pocket of ERK2 using Glide in Schrodinger 9.0. For each system, the binding site was dened based on the known ligand (SCH772984 in 4QTA and compound 1 in 4QYY), and the receptor grid box for docking was set to 25Å Â 25Å Â 25Å using the Receptor Grid Generation protocol of Schrodinger 9.0. Default settings were used for the other parameters.
2.3.1 Rigid receptor docking. During this docking process, the protein was xed while the inhibitors were exible. So, the 27 inhibitors were rstly generated some reasonable conformations and then docked into the binding pocket of ERK2 in Glide, and the extra precision (XP) scoring mode was choosed. 
Induced t docking.
Aer obtained the best bound mode of ERK2 with every studies inhibitor, the induced t docking (IFD) protocol was employed to investigate the importance of ERK2 exibility to ligand binding. The best receptorligand complex was evaluated by the XP scoring and the side chains of the residues within 5Å of each inhibitor is exible.
2.3.3 QM-polarized ligand docking. The QM-Polarized Ligand Docking (QPLD) protocol in Schrodinger was employed to estimate the electrostatic interaction between receptor and ligand more accurately, which combines Glide and the QM/MM method implemented in Q-site. Based on the protein-ligand structures predicted by Glide, G-site computes the partial atomic charges with ab initio method and conducts a single-point energy calculation on each complex. Then, the binding poses are re-ranked based on the updated energies.
2.3.4 Ensemble docking. Aer 10 representative structures were generated from the MD simulations for each complex, the 27 inhibitors were successively docked into the 10 representative structures by using the RRD protocol with the XP scoring mode in Glide, and the pose with the best XP score was saved for each ligand.
Molecular dynamics (MD) simulations
The 27 ERK2-inhibitor complexes obtained by RRD based on the crystal structure of 4QYY were submitted to 5 ns NPT MD simulations (T ¼ 300 K and P ¼ 1 atm). For the details parameters setting of the MD simulations, please see the previous section ''Generation of multiple representative ERK2 protein conformations''. The trajectory for each system was saved every 1 ps for the sampling process.
MM/PB(GB)SA binding free energy calculations and residue decomposition
The Molecular Mechanics/Poisson-Boltzmann Surface Area (MM/PBSA) and Molecular Mechanics/Generalized Born Surface Area (MM/GBSA) method, 35, 36 widely used in elucidating receptor-ligand binding mechanisms, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] [47] [48] were employed to estimate the ERK2-inhibitor binding free energies in AMBER14. In MM/PB(GB)SA, the binding free energy can be decomposed into several terms and 200 snapshots were extracted from the last 3 ns MD trajectory for the free energy calculations. In MM/GBSA, the binding free energy can be calculated as follows:
where hDG bind i is the calculated average free energy, and hDE MM i is the average molecular mechanical energy.
hDG solvation i represents the desolvation free energy upon ligand binding, which is composed of the polar (hDG PB(GB) i) and nonpolar contributions (hDG SA i). The polar contribution of desolvation (hDG PB(GB) i) was calculated based on modied Generalized Born (GB) model (igb ¼ 2) developed by Onufriev and coworkers 49 or the PB model developed by Luo. 50 The solute dielectric constant was set to 1, and the solvent dielectric constant was set to 80. The LCPO method: DG SA ¼ 0.0072 Â DSASA was used to determine the nonpolar contribution (hDG SA i) of the desolvation by using solvent accessible surface area (SASA). The conformation entropy contribution can be calculated using normal-mode analysis, but considering high computational cost and low prediction accuracy, the calculated the conformational entropy contribution (ÀThDSi) upon ligand binding was neglected.
51
Exploring the energy contribution of individual residue to the total binding free energy between the inhibitors and ERK2 is crucial, so the MM/GBSA binding free energy decomposition process 52, 53 was used to decompose the interaction energy to each residue involved in the interaction by considering molecular mechanics and solvation energy without consideration of the contribution of entropy.
Results and discussion
Molecular docking based on the crystal structure
Redocking was used to verify the accuracy of our docking protocols for the two crystal structure 4QTA or 4QYY, which was implied by Glide with XP scoring mode in Schrodinger 2009. The RMSD between the binding pose and the corresponding experimental structure was 0.57 and 0.41Å for 4QTA and 4QYY, respectively, indicating that the Glide RRD has high accuracy to reproduce the experimental binding poses. Then, we docked all the 27 compounds into the active site of ERK2 (4QYY) in Schrodinger 2009, and three different docking protocols RRD, IFD and QPLD were implied. The corresponding docking scores are summarized in Table 1 . The linear correlation between the experimental pIC 50 values and the docking scores was used to evaluate the performance of each docking protocol. As shown in Fig. 2 , the correlation coefficient squares (R 2 ) for RRD, IFD and QPLD are 0.08, 0.16 and 0.04, respectively.
The performance of IFD is better than those of RRD and QPLD, which mean that considering protein exibility is a well method to enhance the docking accuracy. However, IFD can only considers the exibility of residues around the active site, rather than the whole protein. Based on the above analysis, any of the traditional docking methods used above could not correctly rank the binding potencies with a high condence.
3.2 Incorporating exibility and dynamics into the receptor 3.2.1 Docking into an ensemble of ERK2 conformations. MD simulations have been proved to be a successful method to obtain reasonable conformation of receptor-ligand interactions. Therefore, 20 ns MD simulations were employed for the two complexes, and the results show that aer 10 ns, the RMSD of each system tends to converge, indicating that the systems are stable and equilibrated (Fig. S1 †) . The k-means clustering algorithm were used to cluster 200 conformations extracted from the last stable 10 ns trajectory for each ERK2-inhibitors complex, at last 10 representative structures were eventually resolved for each complex (Fig. 3 and S2 †) . Then the 10 representatives as the receptor, 27 inhibitors were docked into the active site of ERK2 by using RRD. MD simulations generated most of conformations have better binding capability to rank the binding potency than the crystal structures (Fig. S3 †) , which indicates that the protein backbones of the conformations extracted from the MD simulations have obvious conformational rearrangement. Above analysis conrms the importance of protein exibility on the prediction of protein-ligand interactions.
However, not all the binding capability of MD conformations is superior to the crystal structure (R 4QTA_4200 2 ¼ 0.07, R 4QYY_1600 2 ¼ 0.00, and R 4QYY_5400 2 ¼ 0.06), which makes us wonder how to choose the reasonable conformation. In fact, it is difficult to determine the reasonable structures beforehand. Therefore, the highest and average docking scores of all the 10 representative conformations for each inhibitor were used to rank the binding affinities of the inhibitors (Fig. 4) (1, 2a, 2b, 3a, 4 , and 8) were analyzed to explore the overall stabilities during the MD simulations. As shown in Fig. 5 and 6 , all the studied systems achieve equilibria aer $2.5 ns. Most of the residues with greater exibility are located in the loop regions, such as P-loop. The residues located in the ATP binding pocket and allosteric pocket bear relatively higher rigidity because they form strong interactions with inhibitors.
The binding free energies and the energy components for each inhibitor-ERK2 system were predicted based on the 200 snapshots using the MM/PBSA and MM/GBSA approaches. binding affinity, but both methods perform better than RRD, IFD, QPLD and even ensemble docking. In addition, the correlations between the individual energy terms and the experimental activities were compared (Fig. S4 †) . The results show As a conclusion, the non-polar contributions are possibly more important than the polar contributions to determine the discrepancy of the binding affinities of the 27 inhibitors.
Furthermore, as shown in Table 2 , the predicted binding affinity of compound 1 (À32.78 kcal mol À1 ) is stronger than those of the derivatives bound with the allosteric pocket (2-3d) or ATP binding pocket (1a, 9-9d) and modications, which is consistent with the experimental results. In addition, the compounds with different terminal substitutions located in the allosteric pocket (2-2b, 3, 4 and 5) display different binding affinities compared with compound 1. The above results predicted by MM/PBSA are basically accordant to the experimental data.
Identication of key residues responsible for inhibitor binding
In order to further identify the key residues for ERK2 binding to inhibitors, as well as understand the possible molecular mechanism of the important substituents that can improve the binding affinity with ERK2, the enthalpy (DG bind,PB ) of representative inhibitors (1, 2a, 2b, 4 and 8) was decomposed into a per-residue depicted in Fig. 8 . According to Fig. 8 , the key residues contributing to the binding progress is: Val37, Lys52, Ile82, Gln103, Leu105, Met106 and Leu154 (the ATP binding pocket) and Tyr34, Pro56, Tyr62, Asp165, Phe166 and Val186 (the allosteric pocket), and the main role of these residues for ERK2 binding inhibitors are hydrogen bonding and hydrophobic interaction. The contributions of the non-polar residues are a very important part of the binding free energies, especially the residues Val37, Lys52, Tyr62, Arg65, Glu69, Met106 and Leu154. The contributions of the polar residues (e.g. Tyr34, Ile54, Met106 and Asp165) are relatively insignicant except for the residues Lys52 and Tyr62, and there is a slight energetic difference between different inhibitors. The pIC 50 values of the compounds 2b, 4 and 8 are about 20 times higher than that of compound 1, while compound 2a shows the lowest activity. Structural analysis shows that these compounds have different substituents interacting with the allosteric pocket region. By further comparing the binding characteristics of the selected inhibitors, we can understand the structural requirements of inhibitors for enhancing binding affinity, which will guide the rational design of more effective and selective ERK2 Type I (Table 2 ). The difference of the energy contributions of Tyr62 between 1 and 2a is the largest (À1.77 kcal mol À1 ). This is because the acetyl group in compound 1 can form stronger non-polar interactions with Tyr62 than the uorophenyl substituent in 2a (Fig. 9) . Besides, the contributions of the residues located in the ATP binding pocket (Tyr34, Val37, Lys52 and Ile54) and Asp165 to the binding of compound 1 are higher than those to the binding of compound 2a, but the difference is not obvious. As shown in Fig. 8 , the two compounds form effective interactions with the residues Tyr34, Lys52, Tyr62, Gln103 and Met106, and these residues mainly locate in the ATP binding pocket and the allosteric pocket. The replacement of the acetyl group in compound 1 by uorophenyl substituent may result in the conformational change of the inhibitors, which lead to the formation of more effective interactions with several residues far away from the allosteric pocket, such as residue Val186. In addition, the residues Glu69 and Asp104 have difference in non-polar interactions ( Fig. 8(b) and (c)), which also may play a critical role in rendering the difference of the binding free energies. , respectively) ( Fig. 9(g) and (h) ). In addition, the contributions of the residues Tyr62 and Gln69 to the compounds 4 and 8 binding are more favorable than those to the compound 1 binding, which can be explained by the fact that the residues Tyr62 and Gln69 tend to form stronger interactions with the terminal substitutions of 4 and 8 ( Fig. 9(C) and (D) ). Detailed structure analysis indicates that the p-p interaction between the Tyr62 side chain and the terminal substitutions of compounds 4 and 8 is stronger than that of compound 1. However, the predicted binding free energy of compound 2b is weaker than that of compound 1, which is supported by the per-residue energy decomposition analysis that Lys52, Thr66, Met106 and Asp165 show more favorable contribution to compound 1 binding than to compound 2b binding (the differences for Lys52, Thr66, Met106 and Asp165 are 2.61, 0.64, 0.92 and 0.72, respectively) ( Fig. 8(d) ), and also is supported by the detailed structure analysis that the instability of the large terminal substitution of compound 2b with the allosteric pocket ( Fig. 9(B) ). (1) Considering the exibility and dynamics behavior of ERK2 is quite important to correctly predict the binding potencies of Type I 1/ 2 inhibitors. MD simulations is an important way to improve protein exibility, and the results indicate that the protein structures obtained from the MD simulations show better tolerance to the ligands. Meanwhile, MD simulations can obviously improve the ranking ability of the binding potencies of the studied ERK2 inhibitors. The binding affinities give the best correlation with the experimental data, which highlighting the importance of incorporating protein exibility in predicting ERK2-inhibitors interactions.
Suggestions for designing of improved
(2) The hydrogen bonds between the side chain of residues Lys52 and Gln103 with inhibitors play a key role in stabilizing the interaction between inhibitors and ERK2. The favorable van der Waals contribution (DE vdW ) is important for improving the interaction between ERK2 and inhibitors, which mainly contributes the non-polar interaction. The hydrophobic contributions may be highly helpful to improve the binding ability of ERK2 inhibitors, and the hydrophobic contributions are mainly from some surrounding key residues, such as Val37, Gln103, Asp104 and Met106. Therefore, potential improved ERK2 inhibitors can be designed by increasing hydrophobic interactions, as well as keeping the hydrogen bounds between ERK2 and ERK2 inhibitors.
(3) The terminal substitute interacts "face to face" with the residue Tyr62 side chain through an aromatic p-p interaction is of signicant importance for improving activities of ERK2 inhibitors. The results given by our calculations and the experimental data show that large terminal substitute is unfavorable for inhibitors, for example compound 2a.
Conclusions
In this work, the binding mechanisms of ERK2 with the Type I 1/2 inhibitors were investigate by molecular docking, ensemble docking, MD simulations and binding free energy calculations. Our prediction results show that it is necessary to consider the exibility of receptor before performing molecular docking to improve the prediction accuracy of traditional docking methods, such as Glide docking, IFD and QPLD. In particular, MD simulations is a well way to improve the exibility and the binding free energies predicted by MM/PBSA protocols show the highest correlation with the experimental data, which investigates the importance of protein exibility to predict ERK2 with the Type I 1/2 inhibitors interactions. The results of binding free energy calculations predicted by MM/PBSA show that the non-polar interactions play determinative roles in the binding of ERK2 inhibitors, which leads to the difference of the binding affinities of the inhibitors. Several possible key residues for inhibitors binding are identied by the binding free energy decomposition analysis. In addition, the comprehensive analysis of several representative inhibitors also demonstrates the importance of hydrophobic and hydrogen bonds interactions between the residues located in the ATP binding pocket and the allosteric pocket and the inhibitors in improving the binding affinities of the inhibitors. We hope our results will provide a deeper understanding of the interaction between the Type I 1/2 inhibitors and ERK2 more valuable information for the further design of new potent ERK2 inhibitors.
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